Review of drugs on uterine leiomyomas

doi:10.19803/j.1672-8629.2022.06.24

Abstract

Abstract: Uterine leiomyomas (fibroids) is one of the most common gynecological tumors. At present, the most effective cure method for uterine fibroids is surgery. Surgical approach includes hysteromyomectomy, total hysterectomy and subtotal hysterectomy. Surgery inevitably reduces fertility and increases the obstetrical risks. In addition, because some uterine fibroids may shrink and become smaller after menopause, which makes some patients with childbearing aspiration choosing non-surgical treatments. This article summarizes the currently commonly used drugs in clinical practice and treatments that may be promising in clinical application.

Key words: uterine leiomyomas (fibroids), drug therapy, ulipristal acetate

CLC Number:

YU Ya, PENG Changsheng, CUI Tao. Review of drugs on uterine leiomyomas[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 465-468.

References

[1] WISE L, PALMER J, STEWART E, et al.Age-specific incidence rates for self-reported uterine leiomyomata in the black women's health study[J]. Obstetrics and Gynecology, 2005, 105(3): 563-568.
[2] MURJI A, WHITAKER L, CHOW T, et al. Selective progesterone receptor modulators (SPRMs) for uterine fibroids[J]. The Cochrane Database of Systematic Reviews, 2017, 4(4): CD010770.
[3] MCWILLIAMS M, CHENNATHUKUZHI V.Recent advances in uterine fibroid etiology[J]. Seminars in Reproductive Medicine, 2017, 35(2): 181-189.
[4] EDWARDS T, GIRI A, HELLWEGE J, et al.A trans-ethnic genome-wide association study of uterine fibroids[J]. Frontiers in Genetics, 2019,10:511.
[5] STEWART E, COOKSON C, GANDOLFO R, et al.Epidemiology of uterine fibroids: a systematic review[J]. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124(10): 1501-1512.
[6] FAUSTINO F, MARTINHO M, REIS J, et al.Update on medical treat-ment of uterine fibroids[J]. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 2017, 216: 61-68.
[7] LETHABY A, VOLLENHOVEN B, SOWTER M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids[J]. The Cochrane Database of Systematic Reviews, 2001(2): CD000547.
[8] LETHABY A, VOLLENHOVEN B, SOWTER M.Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review[J]. BJOG: an International Journal of Obstetrics and Gynaecology, 2002, 109(10): 1097-1108.
[9] CODDINGTON C, COLLINS R, SHAWKER T, et al.Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri[J]. Fertility and Sterility, 1986,45(5):624-629.
[10] BRITTEN J, MALIK M, LEVY G, et al.Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production[J]. Fertility and Ssterility, 2012, 98(5): 1299-1307.
[11] SURREY E, HORNSTEIN M.Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up[J]. Obstetrics and Gynecology, 2002, 99(5 Pt 1): 709-719.
[12] DETTI L, UHLMANN R, ZHANG J, et al.Goserelin fosters bone elongation but does not prevent ovarian damage in cyclophosphamide-treated prepubertal mice[J]. Fertility and Sterility, 2014, 101(4): 1157-1164.
[13] GEORGOPOULOS N, ARMENI A, STAMOU M, et al.Gonadotropin-releasing hormone (GnRH) deficiency under treatment: psychological and sexual functioning impacts[J]. Hormones (Athens, Greece), 2018, 17(3): 383-390.
[14] TOFTAGER M, SYLVEST R, SCHMIDT L, et al.Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome to a randomized controlled trial comparing gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist protocols[J]. Fertility and Sterility, 2018, 109(1): 154-164.
[15] MORONI R, MARTINS W, FERRIANI R, et al. Add-back therapy with GnRH analogues for uterine fibroids[J]. The Cochrane Database of Systematic Reviews, 2015(3): CD010854.
[16] ARCHER D, STEWART E, JAIN R, et al.Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study[J]. Fertility and Sterility, 2017, 108(1): 152-160, e154.
[17] BARRA F, VITALE S, SECA M, et al.The potential role of elagolix for treating uterine bleeding associated to uterine myomas[J]. Expert Opinion on Pharmacotherapy, 2020, 21(12): 1419-1430.
[18] OSUGA Y, SEKI Y, TANIMOTO M, et al.Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endome-triosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study[J]. Fertility and Sterility, 2021, 115(2): 397-405.
[19] ROCCA M, PALUMBO A, LICO D, et al.Relugolix for the treatment of uterine fibroids[J]. Expert Opinion on Pharmacotherapy, 2020, 21(14): 1667-1674.
[20] MACLEAN D, SHI H, FAESSEL H, et al.Medical castration using the investigational oral GnRH antagonist TAK-385 (Relugolix): phase 1 study in healthy males[J]. The Journal of Clinical Endocrinology and Metabolism, 2015, 100(12): 4579-4587.
[21] OSUGA Y, ENYA K, KUDOU K, et al.Oral Gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial[J]. Obstetrics and Gynecology, 2019, 133(3): 423-433.
[22] POHL O, MARCHAND L, FAWKES N, et al.Gonadotropin-releasing hormone receptor antagonist mono- and combination therapy with estradiol/norethindrone acetate add-back: pharmacodynamics and safety of OBE2109[J]. The Journal of Clinical Endocrinology and Metabolism, 2018, 103(2): 497-504.
[23] SHOZU M, MURAKAMI K, INOUE M.Aromatase and leiomyoma of the uterus[J]. Seminars in Reproductive Medicine, 2004, 22(1): 51-60.
[24] ISHIKAWA H, REIERSTAD S, DEMURA M, et al.High aromatase expression in uterine leiomyoma tissues of African-American women[J]. The Journal of Clinical Endocrinology and Metabolism, 2009, 94(5): 1752-1756.
[25] SUMITANI H, SHOZU M, SEGAWA T, et al.In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism[J]. Endocrinology, 2000, 141(10): 3852-3861.
[26] HADJI P, BODY J, AAPRO M, et al.Practical guidance for the management of aromatase inhibitor-associated bone loss[J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2008, 19(8): 1407-1416.